Your email did not fail because of the subject line. It failed because there was no reason for it to arrive today rather than any other day, and the person reading it knew that instantly.
The delete test
A VP of Clinical Operations at a mid-size biotech gets dozens of vendor emails a month. She deletes almost all of them in under two seconds, using a single unconscious test: is this about me, or about them?
“We are a full-service CRO with deep therapeutic expertise” is about them. “Just checking in to see if you have any upcoming needs” is about them, and worse, it is an admission that you have nothing to say. Both fail the test before the second line.
What a trigger changes
Now the same email with a trigger: I saw you closed the Series B and are taking BMN-101 into Phase 2. Rare disease enrollment in that indication is genuinely difficult, and most sponsors underestimate the site activation timeline.
Nothing about your company. No pitch. Just evidence that you are paying attention and that you understand a problem she is about to have. That gets a reply, because it is a message from someone who might actually be useful.
The anatomy of an email that works
- The trigger. Something that actually happened, recently, to them. This is what earns the right to send the email at all.
- The implication. What you understand about the problem that event creates. This is where you demonstrate expertise without claiming any.
- The ask. Small, specific, and easy to say yes to. Not “a 30-minute call to explore synergies.”
Notice what is missing: your capabilities, your client list, your differentiators. None of that belongs in a first email. It is the answer to a question they have not asked yet.
Why most teams cannot do this
Because finding the trigger is the hard part. It means monitoring funding announcements, clinical milestones, regulatory events, M&A and leadership changes across an entire industry, then working out which ones matter for your specific service line, and then finding the right person to contact.
BD reps who attempt this burn ten or more hours a week and are still behind. Most quietly give up and revert to “just checking in,” which is how we got here.
The fix is upstream
Better email templates will not save an email with no trigger. The problem is not the writing. It is that you are writing to people with nothing to say to them.
Fix the input, and the outreach fixes itself.
Know who to call
Your team is writing emails to people they have no reason to email. That is not a copywriting problem. It is an intelligence problem.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
Why does cold email fail in biotech?
Because there is no trigger, so there is no reason the email arrived today rather than any other day, and the recipient knows it instantly. Generic openers like ‘we are a full-service CRO’ or ‘just checking in’ are about the sender rather than the buyer, and they fail before the second line.
What makes a biotech BD email work?
Three things: a trigger, meaning something that actually happened to them recently, which earns the right to send the email at all; the implication, showing you understand the problem that event creates; and a small, specific ask. Notably absent are your capabilities, client list and differentiators, which answer questions nobody asked yet.
How do I find trigger events for outreach?
By monitoring funding announcements, clinical milestones, regulatory events, M&A and leadership changes, then working out which matter for your service line and who to contact. Done manually this consumes ten or more hours a week per rep, which is why most teams give up and revert to generic outreach.
